Drug Type Bispecific antibody |
Synonyms |
Target |
Action agonists, inhibitors, stimulants |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), CEA inhibitors(Carcinoembryonic antigen inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | Switzerland | 02 Sep 2022 | |
Solid tumor | Preclinical | Switzerland | 02 Sep 2022 |